Intravenous Ketorolac Substantially Reduces Opioid Use and Length of Stay After Lumbar Fusion: A Randomized Controlled Trial.

MLA

Iyer, Sravisht, et al. “Intravenous Ketorolac Substantially Reduces Opioid Use and Length of Stay After Lumbar Fusion: A Randomized Controlled Trial.” Spine, vol. 49, no. 2, Jan. 2024, pp. 73–80. EBSCOhost, https://doi.org/10.1097/BRS.0000000000004831.

APA

Iyer, S., Steinhaus, M. E., Kazarian, G. S., Zgonis, E. M., Cunningham, M. E., Farmer, J. C., Kim, H. J., Lebl, D. R., Huang, R. C., Lafage, V., Schwab, F. J., Qureshi, S., Girardi, F. P., Rawlins, B. A., Beckman, J. D., Carrino, J. A., Chazen, J. L., Varghese, J. J., Muzammil, H., … Sandhu, H. S. (2024). Intravenous Ketorolac Substantially Reduces Opioid Use and Length of Stay After Lumbar Fusion: A Randomized Controlled Trial. Spine, 49(2), 73–80. https://doi.org/10.1097/BRS.0000000000004831

Chicago

Iyer, Sravisht, Michael E Steinhaus, Gregory S Kazarian, Evangelia M Zgonis, Matthew E Cunningham, James C Farmer, Han Jo Kim, et al. 2024. “Intravenous Ketorolac Substantially Reduces Opioid Use and Length of Stay After Lumbar Fusion: A Randomized Controlled Trial.” Spine 49 (2): 73–80. doi:10.1097/BRS.0000000000004831.